Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Silvia Ghezzi
Observed name:
S. Ghezzi
Institution:
Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda
Observed institution:
Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda
ORCID:
0009-0000-8798-1152
Observed ORCID:
0009-0000-8798-1152
OpenAlex ID:
A5035771478
Circulating Tumor DNA to Drive Treatment in Metastatic Colorectal Cancer
2023
·
Giorgio Patelli
, Gianluca Mauri
, et al.
·
Clinical Cancer Research
·
45
PDF
Total neoadjuvant therapy followed by non-operative management or surgery in stage II–III rectal cancer (NO-CUT): a multicentre, single-arm, phase 2 trial
2025
·
Alessio Amatu
, Giorgio Patelli
, et al.
·
The Lancet Oncology
·
31
370P Trastuzumab-emtansine (T-DM1) in HER2-amplified metastatic colorectal cancer patients progressing to trastuzumab-lapatinib: The HERACLES RESCUE phase II trial
2022
·
A. Sartore Bianchi
, S. Lonardi
, et al.
·
Annals of Oncology
·
7
Digital workload in oncology trials: A comparative analysis of e-portal usage and operational insights from a single-center experience
2026
·
Stefano Stabile
, Sara Mariano
, et al.
·
Tumori Journal
·
1
26P Response in patient-derived models recapitulates circulating tumor DNA clearance of matched colon cancer patients after adjuvant treatment in the PEGASUS trial
2024
·
G. Mauri
, E. Zanella
, et al.
·
Annals of Oncology
·
1
PDF
61P Neoadjuvant ipilimumab, nivolumab, and high-dose vitamin C in pMMR/MSS colon cancer: Results of the ALFEO pilot study
2026
·
A. Amatu
, F.M. Tosi
, et al.
·
Annals of Oncology
PDF
Management of Increasing Complexity of Phase I Trials: A Retrospective Analysis from the Niguarda Cancer Center Phase I Unit
2026
·
Anna Bombelli
, Noemi Salmistraro
, et al.
·
Therapeutic Innovation & Regulatory Science
82P Intratumoral presence of the genotoxic gut bacteria pks+ E. coli in very early onset colorectal cancer
2025
·
G. Mauri
, A. Sogari
, et al.
·
Annals of Oncology
PDF
111P Neoadjuvant high-dose vitamin C (HDVC) combined with ipilimumab and nivolumab in proficient mismatch repair (pMMR) colon cancer (CC): First safety analysis of ALFEO pilot study
2025
·
A. Amatu
, G. Ferrari
, et al.
·
Annals of Oncology
PDF
Show more works
View as search
Works count:
9
Citation count:
85
H-index:
3
I10-index:
2
Year
Topic
Type